Key Takeaways Repligen posted Q3 EPS of $0.46, which topped estimates and rose from $0.43 a year ago.Total revenues climbed 22% year over year to $189 million, driven by strong product and order growth.RGEN raised its 2025 revenue outlook but tightened EPS guidance, which weighed on investor sentiment.Repligen Corporation (RGEN) reported third-quarter 2025 adjusted earnings per share of 46 cents, which beat the Zacks Consensus Estimate of 42 cents. The company had recorded adjusted earnings of 43 cents per ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Repligen (RGEN) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +9.52%. A quarter ago, it was expected that this drug developer would post earnings of $0.4 per share when it actually produced earnings of $0.37, delivering a surprise of -7.5%.Over the last four quarters, the company ha ...

Repligen (NasdaqGS:RGEN) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsDoug Schenkel - Managing Director and Head of Life Science Tools and DiagnosticsJason Garland - CFOCasey Woodring - VP of Equity ResearchOlivier Loeillot - President and CEOBrandon Couillard - Managing DirectorDaniel Markowitz - VPDan Arias - Managing DirectorLuke Sergott - Director of Healthcare Equity ResearchJacob Johnson - VP of Investor RelationsConference Call ParticipantsAnna Snopkowski - Equity Research A ...

Repligen (NasdaqGS:RGEN) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsDoug Schenkel - Managing Director and Head of Life Science Tools and DiagnosticsJason Garland - CFOCasey Woodring - VP of Equity ResearchOlivier Loeillot - President and CEOBrandon Couillard - Managing DirectorDaniel Markowitz - VPDan Arias - Managing DirectorLuke Sergott - Director of Healthcare Equity ResearchJacob Johnson - VP of Investor RelationsConference Call ParticipantsAnna Snopkowski - Equity Research A ...

Repligen (NasdaqGS:RGEN) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Speaker2Thank you for standing by. My name is Kayla and I will be your conference operator today. At this time, I would like to welcome everyone to the Repligen Corporation earnings release third quarter of 2025. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press STAR followed by t ...

Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance WALTHAM, Mass., October 28, 2025 -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2025, covering the three- and nine- month periods ended September 30, 2025. Provided in this press release a ...

Core Insights - Repligen Corporation reported strong financial results for Q3 2025, achieving 18% organic growth and a total revenue of $189 million, representing a 22% year-over-year increase [2][5][7] - The company raised its full-year revenue guidance to a range of $729 million to $737 million, indicating a projected non-COVID organic growth of 14% to 15.5% [3][5][10] Financial Performance - Q3 2025 revenue was $189 million, up from $155 million in Q3 2024, with a year-over-year increase of 22% as reported and 18% organic [5][7] - Year-to-date revenue for 2025 reached $540 million compared to $467 million for the same period in 2024 [7] - GAAP net income for Q3 2025 was $15 million, compared to a loss of $1 million in Q3 2024, with adjusted net income at $26 million versus $24 million [7][24] Growth Drivers - All franchises experienced double-digit revenue growth, with consumables and capital equipment revenues growing over 20% [6][5] - The Asia Pacific region led geographical growth, also exceeding double digits [6] - The launch of SoloVPE® PLUS contributed to record placements in Process Analytics equipment [6] Financial Guidance - The updated guidance for FY 2025 includes total reported revenue of $729 million to $737 million, with an expected growth rate of 15% to 16% [10] - Adjusted net income guidance is set between $93.5 million and $95 million, with diluted earnings per share projected at $1.65 to $1.68 [10][34] Margin Analysis - Q3 2025 GAAP gross margin improved to 53.2% from 50.0% in Q3 2024, while adjusted gross margin was 53.3% compared to 50.7% [8][29] - Operating margin for Q3 2025 was 8.9%, a significant improvement from a loss margin of (5.1)% in Q3 2024 [8][29] Strategic Initiatives - Repligen announced a strategic partnership with Novasign to integrate digital twin capabilities into its filtration systems [6] - The company continues to focus on innovation and efficiency in bioprocessing technologies, serving biopharmaceutical developers and CDMOs globally [13]

Core Viewpoint - Investors in the Medical - Biomedical and Genetics sector should consider Alkermes (ALKS) and Repligen (RGEN) for potential value opportunities, with ALKS currently presenting a more favorable investment case [1] Valuation Metrics - Alkermes has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Repligen has a Zacks Rank of 4 (Sell) [3] - ALKS has a forward P/E ratio of 16.78, significantly lower than RGEN's forward P/E of 91.29, suggesting that ALKS is undervalued [5] - The PEG ratio for ALKS is 1.37, compared to RGEN's 3.42, indicating that ALKS has a better expected earnings growth relative to its price [5] - ALKS has a P/B ratio of 3.15, while RGEN's P/B ratio is 4.21, further supporting the notion that ALKS is more attractively valued [6] - Based on these valuation metrics, ALKS holds a Value grade of A, whereas RGEN has a Value grade of D, reinforcing the preference for ALKS among value investors [6]

Core Points - Repligen Corporation will report its third quarter 2025 financial results on October 28, 2025, with a conference call scheduled for 8:30 a.m. ET to discuss business updates and financial results for the three- and nine-month periods ended September 30, 2025 [1] - The conference call will be accessible via toll-free numbers for domestic and international callers, and a webcast will be available on the company's Investor Relations website [2] - Repligen Corporation is a global life sciences company focused on developing innovative bioprocessing technologies for the manufacturing of biological drugs, serving biopharmaceutical developers and contract development and manufacturing organizations (CDMOs) [3]